Nearly 50 of the most frequently-prescribed oncology or treatment-related drugs would be ‘underwater’ – or reimbursed at less than acquisition cost – under the payment rate in the Medicare demonstration project recently proposed by the Centers for Medicare and Medicaid Services, according to the Community Oncology Alliance.
In May 9 comments to CMS, the oncology provider organization takes issue with the agency’s claim that the proposed payment...